Modernising resistance testing for an era of antimicrobial resistance

我们致力于为英格兰公共卫生（PHE）的高质量AMR测试带来革命性的变化，采用尖端的新型机器人技术进行抗菌药物敏感性测试（AST）。改进的数据再现性将建立一个新的国际标准，更好地支持患者管理，获得更快、更准确的结果，并改善通过监测项目获得的信息。这支持PHE优先提供强大的基于实验室的AMR监测（英国5年AMR战略的目标之一）。一个新的快速AST平台将安装在两个PHE实验室中，以提供来自医疗保健相关、高遏制和生物威胁生物的AST数据的新维度。自动化高质量AST、遗传（基于全基因组序列）AST结果和新数据维度（如上所述）的三角测量将建立对AMR的无与伦比的理解和知识基础，并创建一个全球无与伦比的展示性下一代AMR表型和基因分型设施。这将是AST的一个新的黄金标准，将鼓励学术，公共和工业部门与PHE的进一步合作，并有利于英国作为AMR检测和监测的世界领导者的声誉。

We seek to revolutionise high quality AMR testing in Public Health England (PHE) with cutting-edge new robotics for antimicrobial susceptibility testing (AST). The improved data reproducibility will set a new international standard, better support patient management with faster and more accurate results, and improve the information gained via surveillance programs. This supports PHE’s priority of providing robust laboratory-based surveillance of AMR (one of the goals of the UK 5-year AMR strategy). A new rapid AST platform will be installed in two PHE labs to provide new dimensions to AST data from healthcare-associated, high containment and biothreat organisms. Triangulation of automated high quality AST, genetic (Whole Genome Sequence based) AST results and the new data dimensions (above) will build a peerless understanding and knowledge base of AMR and create a showcase, next-generation AMR pheno- and genotyping facility that will be unparalleled globally. It will be a new gold-standard in AST that will encourage further collaboration with PHE from the academic, public and industrial sectors and benefit the UK’s reputation as a world leader for AMR detection and surveillance.